EYPT News and Press, EyePoint Pharmaceuticals Inc. From 10/27/21

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...

– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is on...

WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract hi...

WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Exe...

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2021 Earnings Conference Call August 04, 2021 08:30 AM ET Company Participants George Elston - Chief Financial Officer & Head, Corporate Development Nancy Lurker - President & Chief Executive Officer Jay Duker - Chief Strategic Scientific Offic...

EyePoint Pharmaceuticals (NASDAQ:EYPT): Q2 GAAP EPS of -$0.35 beats by $0.09. Revenue of $9.01M (+118.7% Y/Y) beats by $0.31M. Cash and cash equivalents at June 30, 2021 totaled $127.6 million compared to $44.9 million at December 31, 2020. Outlook: We ...

Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track for initial readout in Q4 2021 Net product revenues of $8.7 million versus $3.7 million in Q2 2020, a 136% increase; Management to host a conferen...

WATERTOWN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the formation of its Executi...

WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference ca...

WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the Company expects to ...